SCHEMBL4013164

SCHEMBL4013164

CS(=O)(=O)c1ccccc1S(=O)(=O)Nc1ccc2[nH]nc(O)c2c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ITK Q08881 2/20 0.46
BRD4 O60885 3/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CHEK1 O14757 1/20 0.43
PRKD3 O94806 1/20 0.43
CDK8 P49336 1/20 0.43
LIMK1 P53667 1/20 0.43
ROCK1 Q13464 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
AURKA O14965 3/20 0.42
NTRK1 P04629 2/20 0.42
SGK1 O00141 2/20 0.42
MAPK1 P28482 1/20 0.41
AURKB Q96GD4 2/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
CSNK2A1 P68400 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1460752 0.86 ROCK1 (0.58) ITKBRD4CHEK1PRKD3CDK8
SCHEMBL1459711 0.86 ITK (0.49) ITKBRD4MEN1KMT2ACHEK1
SCHEMBL1460532 0.85 BRD4 (0.50) ITKBRD4MEN1KMT2ACHEK1
SCHEMBL27596506 0.85 BRD4 (0.47) ITKBRD4MEN1KMT2ACHEK1
SCHEMBL4005787 0.85 ITK (0.46) ITKBRD4MEN1KMT2ACHEK1
SCHEMBL4007743 0.85 ITK (0.46) ITKBRD4MEN1KMT2ACHEK1
SCHEMBL1460609 0.85 MAPK1 (0.50) ITKAURKANTRK1SGK1MAPK1
SCHEMBL6554384 0.85 HAO1 (0.56) ITKBRD4CHEK1PRKD3CDK8
SCHEMBL1461718 0.84 ITK (0.46) ITKBRD4MEN1KMT2ACHEK1
SCHEMBL1460552 0.84 MAPK1 (0.54) ITKPRKD3CLK4AURKANTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 ITK 222/4885BRD4 265/4885MEN1 2247/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 ITK 266/4885BRD4 325/4885MEN1 2443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.